Key Insights• According to the research report, "South Korea Diabetes Care Devices Market Outlook, 2031," published by Actual Market Research, the South Korea Diabetes Care Devices Market is anticipated to grow at more than 12.16% CAGR from 2026 to 2031.• The South Korean diabetes care devices market operates under a centralized public reimbursement framework managed by the National Health Insurance Service (NHIS). Following landmark statutory updates, the Ministry of Health and Welfare expanded national insurance subsidies for real-time Continuous Glucose Monitoring (rtCGM) sensors and Automated Insulin Delivery (AID) pumps. Under the current NHI medical device benefit framework (Yoyang-bi scheme), registered Type 1 diabetes patients receive 70% to 90% reimbursement for continuous glucose sensors, transmitters, and automated insulin pumps. Strategic breakthroughs in South Korea center on recent policy revisions broadening reimbursement to cover pediatric cohorts under 19 with lower self-pay thresholds (up to 90%), pregnant women with gestational diabetes, and severe insulin-dependent Type 2 diabetes patients undergoing multiple daily injections.• While international medtech leaders historically controlled high-end continuous tracking, South Korea has achieved major technological breakthroughs in domestic sensor localization and proprietary algorithm development. Local medical technology developers most notably i-SENS with its CareSens Air CGM platform have secured Ministry of Food and Drug Safety (MFDS) clearances for domestic 15-day continuous glucose sensors. Coupled with domestic AI software startups (such as Kakao Healthcare's PASTA platform and EoFlow's tubeless patch pump EAPatch), South Korean manufacturers are successfully integrating hardware with mobile health applications tailored to East Asian dietary metrics.• According to epidemiological statistics from the Korean Diabetes Association (KDA) and the International Diabetes Federation (IDF) Atlas, over 5.03 million adults (aged 20–79) in South Korea are living with diabetes, representing an adult prevalence rate of approximately 9.6%.

Among Korean adults aged 30 and older, diabetes prevalence reaches 15.5%. Crucially, an estimated 25.3% of affected adults remain formally undiagnosed, while over 15 million adults present with prediabetes or impaired fasting glucose. Type 1 diabetes affects over 50,000 individuals across the country. From an economic perspective, public expenditure managed through the NHIS for diabetes consumables and management devices expanded drastically, with annual reimbursement claims for diabetes supplies growing from ₩2.8 billion (~$2.1 million USD) in 2015 to over ₩111.1 billion (~$83 million USD).Market Outlook• The future landscape of South Korea’s diabetes care device sector centers on integrating continuous biosensors into national digital healthcare platforms and expanding outpatient access via community pharmacies (Yak-guk). As the Ministry of Health and Welfare promotes remote patient monitoring (RPM) and digital therapeutics (DTx) fast-track programs, device manufacturers are partnering with local health-tech ecosystems to connect continuous sensors directly into smart hospital systems. Future product roadmaps prioritize prescription-light continuous biosensors, reusable connected pen injectors, and AI-driven mobile apps, allowing primary care physicians and certified diabetes educators to manage stable Type 2 diabetes populations remotely and streamline outpatient visits.• Pre-market safety reviews, clinical trial requirements, and manufacturing quality control certifications are governed nationally by the Ministry of Food and Drug Safety (MFDS), while official reimbursement coding and benefit ceiling reviews fall under HIRA and the NHIS.

Clinical practice standards, research guidelines, and patient advocacy initiatives are led by key professional bodies including the Korean Diabetes Association (KDA), the Korean Endocrine Society (KES), and the Korean Association of Diabetes Teachers. Prominent domestic and international medical technology companies actively driving the commercial marketplace in South Korea include i-SENS, Inc., EoFlow Co., Ltd., Kakao Healthcare, Abbott Korea, Dexcom (distributed via Huons), Medtronic Korea, Roche Diabetes Care Korea, and Ascensia Diabetes Care Korea.Market DynamicsDriver: Mandatory NHIS reimbursement coverageThe primary growth driver for the South Korean diabetes care devices market is the progressive expansion of public coverage under the National Health Insurance Service (NHIS) and its statutory medical device benefit framework (Yoyang-bi scheme). Following Ministry of Health and Welfare mandates, the NHIS fully integrates Continuous Glucose Monitoring (CGM) systems, automated insulin pumps, and sensor consumables into the national reimbursement list, covering up to 70% to 90% of hardware costs for registered patients with Type 1 diabetes and severe insulin-dependent Type 2 diabetes.Challenge: Stringent MFDS regulatory approval barriers, HIRA price controls, and PIPA data restrictionsDespite strong national insurance coverage, medical device commercialization in South Korea is subject to strict regulatory barriers, protracted pricing negotiations, and tight health data privacy laws. Foreign and domestic device manufacturers must undergo rigorous pre-market safety, clinical efficacy, and cybersecurity evaluations managed by the Ministry of Food and Drug Safety (MFDS) to secure marketing clearance. Following MFDS approval, manufacturers must navigate health technology appraisals and benefit ceiling determinations enforced by the Health Insurance Review and Assessment Service (HIRA), which frequently imposes aggressive price caps on imported medical hardware and continuous disposables.Trend: Rise of domestic biosensor localization, AI mobile ecosystems, and hospital EMR integrationA defining trend reshaping South Korea’s diabetes care market is the rapid emergence of domestically developed Continuous Glucose Monitoring (CGM) hardware paired with artificial intelligence (AI)-driven mobile health ecosystems. Local medtech innovators (such as i-SENS with its CareSens Air platform) and digital health leaders (such as Kakao Healthcare with its PASTA platform) are challenging imported brands by launching domestically manufactured continuous sensors integrated with mobile software tailored specifically for East Asian dietary habits and lifestyle metrics.

These platforms connect via Bluetooth to smartphones and automatically sync glycemic data, meal logging, and exercise metrics with hospital Electronic Medical Record (EMR) systems across major tertiary university centers.Segment AnalysisSouth Korea Diabetes Care Devices By Product Type• South Korea’s blood glucose monitoring systems market is evolving around the coexistence of conventional finger-prick meters, continuous glucose monitoring systems, and smartphone-connected health platforms. Consumers increasingly value the ability to review glucose patterns alongside meals, exercise, sleep, and medication routines. Compatibility with Korean-language applications, convenient data sharing with healthcare professionals, and clear visual presentation of glucose trends are important product differentiators. The country’s digitally connected consumer environment creates opportunities for manufacturers to offer user-friendly applications and connected monitoring ecosystems, while reliable sensors, comfortable wearables, and straightforward calibration or troubleshooting instructions remain important for sustained use.• South Korea’s insulin delivery devices market is shaped by interest in precise insulin administration, connected treatment management, and the integration of insulin delivery with continuous glucose monitoring. Conventional insulin pens remain relevant because of their portability and familiarity, while insulin pumps and automated insulin delivery systems appeal to users seeking more individualized management. Compatibility between devices, dependable infusion supplies, and clear access to technical support influence purchasing decisions.

A distinctive opportunity lies in systems that translate glucose information into actionable treatment support without making everyday operation unnecessarily complicated. South Korea Diabetes Care Devices By Disease Type• South Korea’s type 1 diabetes segment is characterized by the need for continuous glucose monitoring, dependable insulin delivery, and coordinated long-term treatment. Real-time CGM, insulin pumps, and automated insulin delivery systems are particularly relevant because they can help users respond to changing glucose levels and reduce the burden of frequent treatment decisions. The Korean Diabetes Association emphasizes appropriate CGM use and structured professional education for people using intensive insulin therapy. This creates opportunities for manufacturers to provide integrated devices, customizable alerts, pediatric-friendly wearables, and practical training resources.• South Korea’s type 2 diabetes segment requires a broad portfolio of monitoring technologies because patients have different needs depending on their treatment regimens and level of glucose control. Conventional meters remain useful for targeted testing, while CGM can provide additional insight into glucose responses to meals, physical activity, and medication. The Korean Diabetes Association recognizes the potential value of continuous monitoring for insulin-treated patients and the selective use of periodic monitoring for some people receiving non-insulin treatment.

This creates opportunities for manufacturers to develop flexible monitoring solutions that balance convenience, affordability, and clinical usefulness. South Korea Diabetes Care Devices By End User • South Korea’s home and self-care segment benefits from the availability of connected health technologies that allow patients to monitor glucose and review results through smartphones and compatible digital platforms. Users increasingly value convenient monitoring, clear trend visualizations, and the ability to share readings with healthcare professionals or family caregivers. Continuous glucose monitors, compact glucose meters, smart insulin pens, and compatible mobile applications serve different needs according to treatment requirements. Product differentiation depends on sensor comfort, battery performance, Korean-language interfaces, simple setup, and reliable technical assistance.• South Korean hospitals play an important role in initiating advanced diabetes technologies, supervising glucose management, and educating patients about device use. Their requirements include reliable measurement performance, appropriate clinical interpretation of monitoring data, compatibility with established treatment protocols, and staff familiarity with connected devices. Continuous glucose monitoring can support clinical assessment when used according to relevant care protocols, while insulin pumps and automated delivery systems require appropriate patient selection and training.• South Korea’s diagnostic centers support diabetes detection, follow-up assessment, and evaluation of glycemic control through laboratory testing and related diagnostic services.

Their operational priorities include standardized procedures, dependable equipment, consistent quality control, and efficient handling of patient samples. An important distinction is that laboratory testing and personal glucose monitoring provide complementary information: laboratory results support clinical assessment, while home meters and CGM systems can reveal glucose patterns between appointments. Opportunities exist for diagnostic providers to improve coordination between laboratory reports, outpatient consultations, and digital monitoring records.• South Korea’s ambulatory surgical centers require diabetes monitoring solutions that support appropriate glucose assessment around outpatient procedures while maintaining efficient clinical workflows. Their priorities include dependable readings, rapid access to results, hygienic device handling, and clear documentation for perioperative teams. Patients may arrive using personal glucose meters, CGM sensors, insulin pens, or insulin pumps, creating a need for staff to understand existing treatment arrangements and follow appropriate device-management protocols. Manufacturers can address this segment through compact monitoring equipment, clear operating instructions, and practical training for clinical personnel.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Diabetes Care Devices Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product Type• Blood Glucose Monitoring Systems• Insulin Delivery DevicesBy Disease Type• Type 1 Diabetes• Type 2 DiabetesBy End User• Home/Self-Care• Hospitals• Diagnostic Centers• Ambulatory Surgical Centers.